Claims for Patent: 7,514,252

Summary for Patent: 7,514,252

Title:	Cell-specific and/or tumor-specific promoter retargeting of herpes .gamma. 34.5 gene expression
Abstract:	The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes .gamma.34.5 gene.
Inventor(s):	Chiocca; E. Antonio (Powell, OH), Chung; Richard Y. (Boston, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	11/042,189
Patent Claims:	1. A herpes viral mutant comprising: (a) a deletion or inactivating mutation in both copies of the gene encoding .gamma.34.5; (b) an insertion of at least one copy of the .gamma.34.5 gene under the transcriptional control of a cell-specific and/or tumor-specific promoter; and (c) at least one additional endogenous deletion or inactivating mutation of a herpes viral gene. 2. The herpes viral mutant of claim 1, wherein said herpes virus is herpes simplex virus type 1. 3. The herpes viral mutant of claim 1, wherein said herpes virus is herpes simplex virus type 2. 4. The herpes viral mutant of claim 2, wherein said endogenous deletion or inactivating mutation of a herpes viral gene is in a gene that encodes ribonucleotide reductase (RR), thymidine kinase (TK), uracil DNA glycosylase (UNG), or dUTPase. 5. The herpes viral mutant of claim 2, further comprising a transgene whose product is cytotoxic to neoplastic cells. 6. The herpes viral mutant of claim 5, wherein said transgene is selected from the group consisting of (a) a gene encoding a product that activates or enhances a chemotherapeutic agent, (b) a cytokine gene, (c) a tumor suppressor gene, and (d) a tumoricidal gene. 7. The herpes viral mutant of claim 6, wherein said transgene is inserted in the .gamma.34.5 deletion or herpes UL40 locus. 8. The herpes viral mutant of claim 6, wherein said transgene encodes a product that activates or enhances a chemotherapeutic agent. 9. The herpes viral mutant of claim 8, wherein said transgene encodes a mammalian cytochrome P450. 10. The herpes viral mutant of claim 9, wherein said mammalian cytochrome P450 is P450 2B1, P450 2B6, P450 2A6, P450 2C6, P450 2C8, P450 2C9, P450 2C11, or P450 3A4. 11. The herpes viral mutant of claim 2, wherein said tumor-specific promoter is DF3 (MUC 1), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate specific antigen (PSA), tyrosinase, B-myb, or c-erbB2. 12. The herpes viral mutant of claim 11, wherein said tumor-specific promoter is B-myb. 13. The herpes viral mutant of claim 4, wherein said tumor-specific promoter is DF3 (MUC 1), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate specific antigen (PSA), tyrosinase, B-myb, or c-erbB2. 14. The herpes viral mutant of claim 2, wherein said cell-specific promoter is endothelial nitric oxide synthase (eNOS) promoter expressed in endothelial cells; vascular endothelial growth factor (VEGF) receptor (flk1) promoter expressed in endothelial cells; insulin promoter expressed in beta cells of the pancreas; promoter of gonadotropin-releasing hormone receptor gene expressed in beta cells of the hypothalamus; matrix metalloproteinase 9 promoter, expressed in osteoclasts and keratinocytes; promoter of parathyroid hormone receptor expressed in bone cells; or dopamine beta-hydroxylase promoter expressed in noradrenergic neurons. 15. The herpes viral mutant of claim 4, wherein said cell-specific promoter is endothelial nitric oxide synthase (eNOS) promoter expressed in endothelial cells; vascular endothelial growth factor (VEGF) receptor (flk 1) promoter expressed in endothelial cells; insulin promoter expressed in beta cells of the pancreas; promoter of gonadotropin-releasing hormone receptor gene expressed in cells of the hypothalamus; matrix metalloproteinase 9 promoter, expressed in osteoclasts and keratinocytes; promoter of parathyroid hormone receptor expressed in bone cells; or dopamine beta-hydroxylase promoter expressed in noradrenergic neurons.

Details for Patent 7,514,252

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-08-31